„Fluticason“ – Versionsunterschied
| [gesichtete Version] | [gesichtete Version] |
Inhalt gelöscht Inhalt hinzugefügt
Präzisierung |
Leyo (Diskussion | Beiträge) K format |
||
Zeile 1:
{{QS-
{{Infobox Chemikalie
| Strukturformel =
| Freiname = Fluticason
| Suchfunktion = C22H27F3O4S
| Andere Namen =
| Summenformel = * C<sub>22</sub>H<sub>27</sub>F<sub>3</sub>O<sub>4</sub>S <small>(Fluticason)</small>
* C<sub>25</sub>H<sub>31</sub>F<sub>3</sub>O<sub>5</sub>S <small>(Fluticason-17-propionat)</small>
| CAS = * 90566-53-3 <small>(Fluticason)</small/>
* 80474-14-2 <small>(Fluticason-17-propionat)</small>
* 397864-44-7 <small>(Fluticasonfuroat)</small/>
| PubChem = 5311101
| ATC-Code = * {{ATC|D07|AC17}}
* {{ATC|R01|AD08}}
* {{ATC|R03|BA05}}
| DrugBank =
| Wirkstoffgruppe =
| Wirkmechanismus =
| Beschreibung =
| Molare Masse = * 444,51 [[Gramm|g]]·[[mol]]<sup>−1</sup> <small>(Fluticason)</small>
* 500,57 [[Gramm|g]]·[[mol]]<sup>−1</sup> <small>(Fluticason-17-propionat)</small>
| pKs =
| Dichte = <!--g·[[Meter|cm]]<sup>−3</sup>-->
Zeile 38:
| S = {{S-Sätze|}}
| MAK =
| LD50 = <!--mg·kg<sup>−1</sup> (Ratte, [[Peroral|p.o.]])-->
}}
Zeile 57:
== Literatur ==
* Jarvis B., Faulds D. (1999): Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs, 57(5),
* Johnson M. (1995): The anti-inflammatory profile of fluticasone propionate. Allergy, 50(23),
* Keating G.M., McCormack P.L. (2007): Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs, 67(16),
* Reynolds N.A., Lyseng-Williamson K.A., Wiseman L.R. (2005): Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 65(12),
* Spencer C.M., Jarvis B. (1999): Salmeterol/fluticasone propionate combination. Drugs, 57(6),
* Staresinic A.G., Sorkness C.A. (2000): Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Expert Opin Pharmacother, 1(6), 1227-1244. PMID 11249490
* [http://www.emea.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000770/WC500028814.pdf Avamys, Zusammenfasuung der Merkmale des Arzneimittels], Stand Dezember 2012, Europäische Arzneimttelagentur.
| |||